Atea Pharmaceuticals, Inc. - COMMON STOCK (AVIR)

Historical Holders from Q4 2020 to Q3 2025

Symbol
AVIR on Nasdaq
CUSIP
04683R106
Type / Class
Equity / COMMON STOCK
Shares outstanding
78.4M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
53.1M
Holdings value
$154M
% of all portfolios
0.003%
Grand Portfolio weight change
+0%
Number of holders
110
Number of buys
43
Number of sells
-45
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Atea Pharmaceuticals, Inc. - COMMON STOCK (AVIR)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 11.6% +70% $29.5M $10.9M 9.1M +59% FMR LLC Nov 28, 2025
Sommadossi Jean-Pierre 10.1% $26.2M 8.88M Jean-Pierre Sommadossi Mar 31, 2025
BML Investment Partners, L.P. 8.5% $21.3M 7.22M Leonard Braden Michael Dec 13, 2024
BlackRock, Inc. 7.1% $17.9M 6.08M BlackRock, Inc. Mar 31, 2025
Radoff Bradley Louis 4% +10% $9.97M $811K 3.38M +8.86% Radoff Bradley Louis Apr 16, 2025
EcoR1 Capital, LLC 4% $9.86M 3.34M EcoR1 Capital, LLC Dec 31, 2024

Institutional Holders of Atea Pharmaceuticals, Inc. - COMMON STOCK (AVIR)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 53.1M $154M +$875K $2.90 110
2025 Q2 52.7M $190M -$497K $3.60 105
2025 Q1 52.9M $158M -$11.4M $2.99 102
2024 Q4 56.3M $189M -$6.77M $3.35 103
2024 Q3 57.9M $194M +$4.53M $3.35 105
2024 Q2 56.7M $188M +$7.27M $3.31 101
2024 Q1 54.3M $219M -$1.78M $4.04 111
2023 Q4 55.1M $168M -$1.58M $3.05 106
2023 Q3 56.8M $170M -$2.35M $3.00 116
2023 Q2 57M $213M +$971K $3.74 131
2023 Q1 56.8M $190M -$5.88M $3.35 128
2022 Q4 57.8M $278M -$5.13M $4.81 131
2022 Q3 57.4M $327M -$1.74M $5.69 114
2022 Q2 57.6M $409M +$19.5M $7.10 122
2022 Q1 54.9M $397M +$6.37M $7.22 122
2021 Q4 53.6M $479M -$368M $8.94 138
2021 Q3 56.8M $1.99B -$21.7M $35.06 141
2021 Q2 58.9M $1.27B +$161M $21.48 101
2021 Q1 47.4M $2.91B +$30.5M $61.75 79
2020 Q4 49.9M $2.07B +$1.82B $41.78 69